NASDAQ: LABTLakewood Amedex Biotherapeutics Inc Stock
$7.35-1.30 (-15.03%)
Updated Apr 24, 2026
LABT Price
$7.35
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$5.75
52 Week High
$9.82
P/E
-8.75x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$3.85M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.25
Operating Cash Flow
-$2M
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LABT's potential to beat the market
- LABT doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LABT
RankedUnranked of 467
RankedUnranked of 467
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.57 | A | |
| $196.52 | A | |
| $7.54 | A |
Be the first to know about important LABT news, forecast changes, insider trades & much more!
LABT News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LABT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LABT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LABT is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
LABT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more LABT due diligence checks available for Premium users.
Valuation
LABT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.75x
Industry
20.28x
Market
35.58x
LABT's financial health
Profit margin
Revenue
$0.0
Net Income
-$744.9k
Profit Margin
0%
LABT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$481.6k
Liabilities
$2.4M
Debt to equity
-1.25
LABT's short-term liabilities ($2.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LABT's short-term assets ($305.39k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LABT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LABT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$422.0k
Investing
$0.0
Financing
$0.0
LABT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
Lakewood Amedex Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.